Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results

被引：0

作者：

Mantegazza, Renato ^{[1
]}

Bril, Vera ^{[2
]}

Vu, Tuan ^{[3
]}

Karam, Chafic ^{[4
]}

Peric, Stojan ^{[5
]}

Margania, Temur ^{[6
]}

Murai, Hiroyuki ^{[7
]}

Bilinska, Malgorzata ^{[8
]}

Shakarishvili, Roman ^{[9
]}

Smilowski, Marek ^{[10
]}

Guglietta, Antonio ^{[11
]}

Ulrichts, Peter ^{[11
]}

Vangeneugden, Tony ^{[11
]}

Utsugisawa, Kimiaki ^{[12
]}

Verschuuren, Jan ^{[13
]}

Howard, James ^{[14
]}

机构：

[1] Fdn IRCCS Ist Neurol Carlo Besta, Neurol Iv Neuroimmunol & Neuromuscular Dis Unit, Milan, Italy

[2] Univ Toronto, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada

[3] Univ S Florida, Morsani Coll Med, Neurol, Tampa, FL 33620 USA

[4] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[5] Univ Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia

[6] New Hosp, Dept Neurol & Neurorehabil, Tbilisi, Georgia

[7] Int Univ Hlth & Welf, Neurol, Tokyo, Japan

[8] Wroclaw Med Univ, Dept & Clin Neurol, Wroclaw, Poland

[9] Sarajishvili Inst Neurol & Neurosurg, Neurol, Tbilisi, Poland

[10] Med Univ Silesia, Dept Hematol & Bone Marrow Transplantat, Katowice, Poland

[11] Argenx, Clin Dev, Ghent, Belgium

[12] Hanamaki Gen Hosp, Neurol, Hanamaki, Japan

[13] Leiden Univ, Med Ctr, Neurol, Leiden, Netherlands

[14] Univ N Carolina, Neurol, Chapel Hill, NC 27515 USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2021年 / 429卷

关键词：

D O I：

10.1016/j.jns.2021.117764

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

117764

引用

页数：1

共 50 条

[1] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
Mantegazza, R.
Bril, V.
Vu, T.
Karam, C.
Peric, S.
Margania, T.
Murai, H.
Biliska, M.
Shakarishvili, R.
Smilowski, M.
Guglietta, A.
Ulrichts, P.
Vangeneugden, T.
Utsugisawa, K.
Verschuuren, J.
Howard, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
[2] Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study
Howard, James
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
Murai, Hiroyuki
Guglietta, Antonio
Ulrichts, Peter
Vangeneugden, Tony
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
NEUROLOGY, 2021, 96 (15)
[3] TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
Howard, J.
Vu, T.
Bril, V.
Peric, S.
Verschuuren, J.
Mantegazza, R.
Murai, H.
Ulrichts, P.
Guglietta, A.
de Haard, H.
Parys, W.
Beydoun, S.
Pasnoor, M.
Karam, C.
Muppidi, Sr
Bertorini, T.
Bhavaraju-Sanka, R.
Li, Y.
MUSCLE & NERVE, 2020, 62 : S125 - S126
[4] LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY
Howard, James F., Jr.
Bril, Vera
Tuan Vu
Karam, Chafic
Peric, Stojan
De Bleecker, Jan L.
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
T'joen, Caroline
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
MUSCLE & NERVE, 2022, 65 : S9 - S10
[5] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY
Howard, James
Bril, Vera
Tuan Vu
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
T'joen, Caroline
Utsugisawa, Kimiaki
Mantegazza, Renato
MUSCLE & NERVE, 2022, 66 : S57 - S57
[6] Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT plus Study
Howard, James
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
Ulrichts, Peter
T'joen, Caroline
Brauer, Edward
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
NEUROLOGY, 2022, 99 (23) : S37 - S38
[7] ADAPT: A PHASE 3 STUDY OF FCRN ANTAGONIST, EFGARTIGIMOD, IN MYASTHENIA GRAVIS
Howard, James
Tuan Vu
Bril, Vera
De Bleecker, Jan
Verschuuren, Jan
Mantegazza, Renato
Meisel, Andreas
Peric, Stojan
de Haard, Hans
Parys, Wim
Guglietta, Antonio
Ulrichts, Peter
Murai, Hiroyuki
MUSCLE & NERVE, 2020, 62 : S76 - S76
[8] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT plus Study
Pasnoor, Mamatha
Bril, Vera
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Vu, Tuan
Ulrichts, Peter
Van Hoorick, Benjamin
T'joen, Caroline
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
Howard, James
NEUROLOGY, 2023, 100 (17)
[9] Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT plus study
Bril, Vera
Pasnoor, Mamatha
Karam, Chafic
Peric, Stojan
De Bleecker, Jan L.
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Vu, Tuan
Ulrichts, Peter
Van Hoorick, Benjamin
T'Joen, Caroline
Kaprielian, Roger
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
Howard, James F., Jr.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[10] Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT plus study
Ashcraft, E.
Bril, V.
Pasnoor, M.
Karam, C.
Peric, S.
De Bleecker, J.
Murai, H.
Meisel, A.
Beydoun, S.
Vu, T.
Ulrichts, P.
Van Hoorick, B.
T'joen, C.
Utsugisawa, K.
Verschuuren, J.
Mantegazza, R.
Howard, J.
NEUROMUSCULAR DISORDERS, 2023, 33 : S179 - S179

← 1 2 3 4 5 →